
  
    
      
        
        There_RB are_VBP at_IN least_JJS 300_CD million_CD acute_JJ cases_NNS of_IN malaria_NN each_DT year_NN globally_RB ,_, resulting_VBG in_IN
        more_JJR than_IN a_DT million_CD deaths_NNS ._. Ninety_CD percent_NN of_IN deaths_NNS due_JJ to_TO malaria_NN occur_VB in_IN Africa_NNP ,_, south_RB
        of_IN the_DT Sahara_NNP ,_, mostly_RB in_IN young_JJ children_NNS ._. The_DT number_NN of_IN deaths_NNS is_VBZ increasing_VBG ,_, and_CC one_CD key_JJ
        factor_NN linked_VBN to_TO this_DT has_VBZ been_VBN widespread_JJ drug_NN resistance_NN of_IN 
        Plasmodium_NNP falciparum_NN to_TO conventional_JJ antimalarials_NNS ,_, such_JJ as_IN
        sulfadoxine-pyrimethamine_JJ (_( SP_NNP )_) ;_: such_JJ resistance_NN is_VBZ widespread_JJ in_IN southeast_NN Asia_NNP ,_, South_NNP
        America_NNP ,_, and_CC Africa_NNP ._. The_DT inappropriate_JJ use_NN of_IN antimalarials_NNS during_IN the_DT past_JJ century_NN has_VBZ
        contributed_VBN to_TO this_DT increase_NN in_IN resistance_NN ._. For_IN example_NN ,_, there_EX has_VBZ been_VBN overreliance_NN on_IN
        quinolines_NNS (_( such_JJ as_IN chloroquine_NN )_) and_CC antifolates_NNS (_( such_JJ as_IN pyrimethamine_NN )_) resulting_VBG in_IN
        cross-resistance_JJ among_IN these_DT drug_NN classes_NNS ._. However_RB ,_, in_IN the_DT past_JJ decade_NN ,_, a_DT new_JJ group_NN of_IN
        antimalarials—the_NN artemisinin_NN compounds_NNS ,_, such_JJ as_IN artesunate_NN ,_, artemether_NN ,_, and_CC
        dihydroartemisinin—have_NN been_VBN deployed_VBN on_IN an_DT increasingly_RB large_JJ scale_NN ._.
        These_DT compounds_NNS produce_VBP a_DT very_RB rapid_JJ therapeutic_JJ response_NN ,_, are_VBP active_JJ against_IN parasites_NNS
        resistant_JJ to_TO multiple_JJ drugs_NNS ,_, are_VBP well_RB tolerated_JJ ,_, and_CC reduce_VB gametocyte_NN carriage_NN ._. To_TO date_NN ,_,
        no_DT parasite_NN resistance_NN to_TO these_DT compounds_NNS has_VBZ been_VBN detected_VBN ._.
        If_IN used_VBN alone_RB ,_, the_DT artemisinins_NNS will_MD cure_VB falciparum_NN malaria_NN in_IN seven_CD days_NNS ,_, but_CC studies_NNS
        in_IN southeast_NN Asia_NNP have_VBP shown_VBN that_IN combinations_NNS of_IN artemisinin_NN compounds_NNS with_IN certain_JJ
        synthetic_JJ drugs_NNS produce_VBP high_JJ cure_NN rates_NNS after_IN just_RB three_CD days_NNS of_IN treatment_NN ._. There_EX is_VBZ also_RB
        some_DT evidence_NN that_IN combinations_NNS of_IN therapies_NNS could_MD greatly_RB retard_VB development_NN of_IN resistance_NN
        to_TO the_DT partner_NN drug_NN ._. Although_IN combinations_NNS including_VBG artemisinins_NNS have_VBP been_VBN widely_RB
        advocated_VBN ,_, they_PRP are_VBP expensive_JJ and_CC relatively_RB untested_JJ in_IN highly_RB endemic_JJ areas_NNS ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Adoke_NNP Yeka_NNP and_CC colleagues_NNS compared_VBD artemisinin-based_JJ
        compounds_NNS and_CC other_JJ combination_NN therapies_NNS in_IN four_CD districts_NNS with_IN varying_VBG transmission_NN
        intensity_NN in_IN Uganda_NNP in_IN 2_CD ,_, 160_CD patients_NNS aged_VBN six_CD months_NNS or_CC greater_JJR with_IN uncomplicated_JJ
        falciparum_NN malaria_NN ._. The_DT team_NN tested_VBD the_DT combination_NN of_IN chloroquine_NN and_CC SP_NNP ,_, currently_RB the_DT
        first-line_JJ therapy_NN in_IN Uganda_NNP ,_, the_DT combination_NN of_IN amodiaquine_NN and_CC SP_NNP ,_, a_DT cheap_JJ regimen_NN proven_VBN
        to_TO be_VB efficacious_JJ in_IN previous_JJ trials_NNS ,_, and_CC the_DT combination_NN of_IN amodiaquine_NN and_CC
        artesunate_NN ._.
        During_IN the_DT 28_CD -_: day_NN study_NN they_PRP collected_VBD data_NNS on_IN the_DT efficacy_NN of_IN the_DT different_JJ regimens_NNS
        and_CC examined_VBD the_DT effect_NN on_IN recrudescence_NN and_CC new_JJ infections_NNS after_IN therapy_NN ._. Combined_VBN
        amodiaquine_NN and_CC artesunate_NN was_VBD the_DT most_RBS efficacious_JJ regimen_NN for_IN preventing_VBG recrudescence_NN ,_,
        but_CC this_DT benefit_NN was_VBD outweighed_VBN by_IN an_DT increased_VBN risk_NN of_IN new_JJ infection_NN ._. This_DT result_NN was_VBD
        probably_RB due_JJ to_TO artesunate_NN being_VBG rapidly_RB eliminated_VBN ,_, leaving_VBG only_RB amodiaquine_NN to_TO provide_VB
        post-treatment_JJ prophylaxis_NNS ._. Considering_VBG all_DT recurrent_JJ infections_NNS ,_, the_DT combination_NN of_IN
        amodiaquine_NN and_CC SP_NNP was_VBD at_IN least_JJS as_RB efficacious_JJ as_IN the_DT other_JJ combinations_NNS at_IN all_DT sites_NNS and_CC
        superior_JJ at_IN the_DT highest_JJS transmission_NN sites_NNS ._.
        In_IN all_DT ,_, 72_CD %_NN of_IN all_DT recurrent_JJ infections_NNS were_VBD due_JJ to_TO new_JJ infections_NNS ,_, and_CC with_IN the_DT two_CD
        most_RBS efficacious_JJ regimens_NNS (_( amodiaquine_NN and_CC SP_NNP ,_, and_CC amodiaquine_NN and_CC artesunate_NN )_) this_DT
        proportion_NN was_VBD 80_CD %_NN ._. The_DT identification_NN of_IN new_JJ infections_NNS stressed_VBD the_DT need_NN for_IN other_JJ
        malaria_NN control_NN measures_NNS ,_, such_JJ as_IN bed_NN nets_NNS ,_, said_VBD the_DT authors_NNS ._.
        They_PRP also_RB suggested_VBD that_IN antimalarials_NNS should_MD be_VB judged_VBN not_RB just_RB on_IN their_PRP$ impact_NN on_IN
        recrudescence_NN but_CC also_RB on_IN their_PRP$ impact_NN on_IN the_DT risk_NN of_IN new_JJ infections_NNS after_IN therapy_NN ._.
        Previous_JJ studies_NNS have_VBP suggested_VBN that_IN patients_NNS who_WP suffer_VBP recrudescence_NN have_VBP a_DT higher_JJR risk_NN
        of_IN complicated_VBN malaria_NN and_CC death_NN ._. Artemisinins_NNP are_VBP highly_RB attractive_JJ antimalarials_NNS ,_, but_CC
        when_WRB used_VBN as_IN monotherapy_NN ,_, they_PRP have_VBP a_DT high_JJ risk_NN of_IN recrudescence_NN and_CC hence_RB must_MD be_VB combined_VBN
        with_IN other_JJ antimalarials_NNS to_TO achieve_VB maximum_NN efficacy_NN ._. But_CC whether_IN the_DT partner_NN drug_NN should_MD
        be_VB long_JJ or_CC short_JJ acting_NN remains_VBZ unclear_JJ ,_, said_VBD the_DT authors_NNS ._.
        Altogether_RB ,_, artemisinin_NN combinations_NNS offer_VBP great_JJ hope_NN for_IN Africa_NNP ,_, the_DT authors_NNS say_VBP ,_,
        although_IN the_DT ideal_JJ combination_NN regimen_NN remains_VBZ uncertain_JJ and_CC cost_NN is_VBZ a_DT problem_NN ._. To_TO compare_VB
        the_DT efficacy_NN of_IN the_DT different_JJ therapies_NNS ,_, bigger_JJR and_CC longer_JJR controlled_VBN trials_NNS are_VBP needed_VBN in_IN
        conditions_NNS of_IN varied_JJ transmission_NN intensity_NN ._. Nevertheless_RB ,_, based_VBN on_IN the_DT results_NNS of_IN this_DT
        study_NN and_CC others_NNS ,_, Uganda_NNP has_VBZ chosen_VBN a_DT combination_NN of_IN artemether_NN and_CC lumefantrine_NN as_IN its_PRP$
        first-line_JJ therapy_NN against_IN malaria_NN ._.
      
    
  
